Aritinercept

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAritinercept

Drug Alias NameAUR-200AUR200

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionB-cell activating factor receptor inhibitorsTumor necrosis factor ligand superfamily member 13 inhibitors

TargetsB-cell activating factor receptorTumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsAutoimmune DiseasesMyasthenia Gravis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesThunderbolt Pharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesAurinia Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesMyasthenia Gravis

Inactive IndicationsN/A

Other Information

ATC CodeN/A